In 2019, Heyn et al. identified three patients with two novel variants (c.988T > C, c.997G > A) of DNMT3A who showed clinical manifestations of growth restriction, microcephaly, and impaired intellectual impairment (1). Here, DNMT3A is linked to microcephaly.